{
  "id": 5066,
  "text": "J Clin Oncol 2020;38:1-10.2 Naumann RW, Hollebecque A, Meyer T, et al.Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: J Clin Oncol 2020;38:1-10.2 Naumann RW, Hollebecque A, Meyer T, et al.Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "纳武利尤单抗在复发或转移性宫颈癌中的安全性和疗效在CheckMate 358临床试验中进行了评估。研究结果显示，纳武利尤单抗作为单药治疗在此类患者中表现出了一定的疗效。具体地，试验观察到部分患者对治疗产生了积极的反应，这表明纳武利尤单抗具有抗肿瘤活性。此外，关于安全性方面，纳武利尤单抗整体耐受性较好，大多数不良事件的严重程度为轻至中度，并且可以管理。这些发现支持纳武利尤单抗作为治疗复发或转移性宫颈癌的潜在选择。",
  "query": "根据临床试验CheckMate 358的结果，评价纳武利尤单抗在复发或转移性宫颈癌中的安全性和疗效有哪些发现？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 根据临床试验CheckMate 358的结果，评价纳武利尤单抗在复发或转移性宫颈癌中的安全性和疗效有哪些发现？\n\n<reference text>: J Clin Oncol 2020;38:1-10.2 Naumann RW, Hollebecque A, Meyer T, et al.Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "纳武利尤单抗在复发或转移性宫颈癌中的安全性和疗效在CheckMate 358临床试验中进行了评估。研究结果显示，纳武利尤单抗作为单药治疗在此类患者中表现出了一定的疗效。具体地，试验观察到部分患者对治疗产生了积极的反应，这表明纳武利尤单抗具有抗肿瘤活性。此外，关于安全性方面，纳武利尤单抗整体耐受性较好，大多数不良事件的严重程度为轻至中度，并且可以管理。这些发现支持纳武利尤单抗作为治疗复发或转移性宫颈癌的潜在选择。"
}